Regenerative Patch Technologies

What Regenerative Patch Technologies does

Regenerative Patch Technologies LLC (RPT) is a California-based, clinical-stage biotechnology company developing a stem cell-based subretinal implant, CPCB-RPE1, for the treatment of geographic atrophy, the advanced form of dry age-related macular degeneration (AMD). The lead product is a bioengineered implant consisting of a polarized monolayer of human embryonic stem cell-derived retinal pigmented epithelial (hESC-RPE) cells on an ultrathin synthetic parylene substrate designed to mimic Bruch's membrane, intended to replace the degenerated RPE cell layer and Bruch's membrane in patients with severe vision loss. RPT has also developed a proprietary xeno-free cryopreservation technique enabling long-term storage and shipment of the implant to clinical treatment sites, addressing a major scalability constraint for cell-based therapies.

The company was founded in 2011 by Dr. Mark Humayun and Dr. David R. Hinton (USC) together with Dr. Dennis O. Clegg (UC Santa Barbara), with core technology exclusively licensed from USC, Caltech, and UC Santa Barbara. RPT completed a Phase I/IIa clinical study with a mean follow-up of 36.9 months in which 27% of treated eyes showed a >5-letter gain in visual acuity versus 7% of untreated fellow eyes, and initiated a randomized, multicenter Phase IIb PATCH AMD trial (NCT06557460) in December 2025 at sites in California, Illinois, and Texas.

RPT is pre-revenue: the implant is investigational and restricted to use within the current clinical trial, with no products on market and no licensing royalties disclosed. Operating capital has been provided by a $12.4 million CIRM grant (July 2023), the Marcus Foundation, and the University of Southern California. The go-to-market pathway is enterprise healthcare-channel: vitreo-retinal surgeons at clinical treatment sites performing outpatient subretinal implantation, with eventual commercial economics tied to per-implant pricing in the ophthalmic surgical market. Target customers are ophthalmologists, retina specialists, and the roughly 1 million US patients (8 million+ worldwide) with geographic atrophy.

Name

Regenerative Patch Technologies

Legal name

Regenerative Patch Technologies LLC

Website

https://regenerativepatch.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Regenerative Patch Technologies is a California-based, clinical-stage biotech developing CPCB-RPE1, a stem cell-derived retinal pigment epithelial cell implant on a synthetic parylene substrate, to restore vision in patients with geographic atrophy (advanced dry AMD). It is pre-revenue and currently running a multicenter Phase IIb trial.

Ownership category

akta.pro rank

Product category

Cell-Based Retinal Implants

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)

akta.pro primary industry

Ophthalmic Regeneration (cornea/retina) (HLAAAGAK)

akta.pro secondary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

Keywords

• Stem cell therapy
• Retinal implant technology
• Macular degeneration treatment
• Bioengineered cell implants
• Ophthalmic biotechnology

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. CPCB-RPE1 Implant (Future): Pre-revenue clinical-stage company. The company is developing a stem cell-based implant for treatment of geographic atrophy (advanced dry AMD). Revenue will likely come from product sales upon regulatory approval. The implant is exclusively for use within current clinical trials and not available for other experimental indications or compassionate use.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Regenerative Patch Technologies (RPT) is a clinical-stage biotechnology company developing a stem cell-based subretinal implant (CPCB-RPE1) for the treatment of geographic atrophy (advanced dry age-related macular degeneration). The implant consists of a polarized monolayer of human embryonic stem cell-derived retinal pigmented epithelial (hESC-RPE) cells on an ultrathin synthetic parylene substrate designed to mimic Bruch's membrane, replacing the damaged RPE cell layer and Bruch's membrane to restore vision.

Product overview

Regenerative Patch Technologies (RPT) is a clinical-stage biotechnology company developing cell-based implant technology for retinal diseases. The company operates with a single lead product: the CPCB-RPE1 implant, a bioengineered subretinal implant consisting of a polarized monolayer of human embryonic stem cell-derived RPE cells on an ultrathin synthetic parylene substrate designed to mimic Bruch's membrane. The implant is designed to replace damaged RPE cells and Bruch's membrane in patients with geographic atrophy (advanced dry AMD). RPT has developed a cryopreserved formulation variant of the implant that enables long-term storage and distribution to clinical sites.

Differentiator

Problem solved

Functional benefit

Products and services

• CPCB-RPE1 Implant A bioengineered subretinal implant consisting of a polarized monolayer of human embryonic stem cell-derived retinal pigmented epithelial (hESC-RPE) cells on an ultrathin synthetic parylene substrate designed to mimic Bruch's membrane. It is intended to replace damaged RPE cells and Bruch's membrane in patients with geographic atrophy (advanced dry age-related macular degeneration) and is exclusively licensed from USC, Caltech, and UC Santa Barbara.
• Cryopreserved CPCB-RPE1 Formulation A cryopreserved long-term storage format of the CPCB-RPE1 implant that facilitates shipment to clinical treatment sites and increases the number of geographic atrophy patients able to receive treatment. The xeno-free cryopreservation technique preserves viable and functional RPE cells in vitro and in vivo.

Quantifiable outcome

• 27% of treated eyes showed >5 letter gain in visual acuity compared to 7% of untreated fellow eyes (Phase I/IIa)
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• University of Southern CaliforniacoreStrategic or Co-development PartnerRPT was founded by Drs. Mark Humayun and David R. Hinton from USC. Technology to produce the CPCB-RPE1 implant is exclusively licensed from USC Stevens Center for Innovation. USC provided funding for clinical trials. Dr. Humayun is Co-Principal Investigator of The California Project to Cure Blindness.
• California Institute of TechnologycoreStrategic or Co-development PartnerTechnology to produce the CPCB-RPE1 implant is exclusively licensed to RPT from Caltech.
• University of California, Santa BarbaracoreStrategic or Co-development PartnerRPT was co-founded by Dr. Dennis O. Clegg from UCSB. Technology to produce the CPCB-RPE1 implant is exclusively licensed from UC Santa Barbara. Dr. Lincoln V. Johnson previously served as Director of the Center for the Study of Macular Degeneration and Associate Director of the Neuroscience Research Institute at UCSB. UCSB Center for Stem Cell Biology and Engineering is involved in the research.
• Retina Center of OhiominorStrategic or Co-development PartnerDr. Suber Huang, MD, MBA, FASRS and Chief Executive Officer of the Retina Center of Ohio, serves as a clinical advisor and has commented on the importance of the Phase IIb clinical trial for geographic atrophy treatment development.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/regenerative-patch-technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regenerative Patch Technologies